AHA today urged the Food and Drug Administration to take “any and all steps possible” to resolve worsening shortages of small-volume parenteral solutions that are fundamental to patient care in hospitals. “We are concerned that the shortages of widely-used and critical products are quickly becoming a crisis and looming threat to the public’s health,” wrote AHA Executive Vice President Tom Nickels. “Therefore, we call on the FDA to vigorously pursue strategies with the current manufacturers of these products and to seek out new suppliers in order to ameliorate the current shortage, as well as prevent such shortages from occurring in the future.” Current shortages of small-volume parenteral solutions include 50 and 100 milliliter injection bags of sodium chloride 0.9%, dextrose 5% and intravenous nutritional products.

Related News Articles

Headline
The AHA today submitted to the Food and Drug Administration legislative, regulatory and best practice recommendations to address new and chronic prescription…
Headline
The Food and Drug Administration yesterday released revised draft guidance for facilities that compound human drugs as outsourcing facilities.
Headline
The AHA, American Society of Anesthesiologists, American Society of Clinical Oncology, American Society of Health-System Pharmacists, and Institute for Safe…
Headline
The Food and Drug Administration yesterday warned the health care community about complications that arise when pairing pain medications with intrathecal…
Headline
Oct. 27 is National Prescription Drug Take Back Day, an opportunity for the public to safely dispose of unwanted or expired prescription pills at sites…
Headline
The Food and Drug Administration yesterday released a series of guidance documents intended to help manufacturers develop generic transdermal and topical…